Physician profile
Dennis James Lang
NPI 1730307463
$8,394.49
in general payments reported to CMS, 2019-2025
31 companies · $1,084 in 2025
The $1,084 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,239 · 2020: $647 · 2021: $1,187 · 2022: $1,476 · 2023: $1,423 · 2024: $1,340 · 2025: $1,084.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,846.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,846.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,461.59 | 2019-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $1,222.25 | 2019-2025 | Lifevest |
| Amgen INC. | $980.63 | 2019-2025 | Repatha, Repatha |
| Alnylam Pharmaceuticals INC. | $585.85 | 2021-2025 | Onpattro, Amvuttra |
| Merck Sharp & Dohme LLC | $545.23 | 2021-2025 | Verquvo, Capvaxive |
| Pfizer INC. | $459.21 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $441.48 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $431.12 | 2020-2025 | Farxiga, Wainua |
| Sanofi-Aventis U.S. LLC | $373.20 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $276.16 | 2019-2024 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $242.43 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $209.46 | 2022-2025 | |
| Scpharmaceuticals INC. | $208.95 | 2023-2025 | |
| Kowa Pharmaceuticals America, INC. | $145.32 | 2019-2022 | |
| Novo Nordisk INC | $95.80 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $92.09 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Edwards Lifesciences Corporation | $75.91 | 2019-2025 | Sapien 3 Ultra Resilia |
| Philips North America LLC | $71.39 | 2022-2025 | Event, (Ck4) Mcot |
| Vital Connect, INC | $70.81 | 2023-2025 | Vitalpatch Rtm |
| Regeneron Healthcare Solutions, INC. | $69.27 | 2019-2020 | |
| Boston Scientific Corporation | $60.83 | 2023-2024 | Watchman Flx |
| Cvrx, INC. | $56.74 | 2024-2025 | Barostim Neo System |
| Amarin Pharma, INC. | $55.69 | 2019-2021 | |
| Abbott Laboratories | $44.89 | 2022-2025 | Amplatzer Amulet |
| Corcept Therapeutics | $22.95 | 2025 | Korlym |
| Kiniksa Pharmaceuticals International, Plc | $21.75 | 2024 | Arcalyst |
| G Medical Diagnostic Services, INC. | $17.90 | 2022 | |
| Cleerly, INC. | $15.54 | 2024 | Cleerly Labs, Cleerly Ischemia |
| Arbor Pharmaceuticals, INC. | $14.86 | 2019 | |
| Preventice Services, LLC | $13.91 | 2019 | |
| Amryt Pharma Holdings LTD | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dennis Lang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.